💥 TRENDING: Gallery - High Quality
ONE WORLD | ONE FIGHT
Global Platform for Breast Cancer and other Female Cancers
Fund the science that saves lives.
85% of every donation funds research →Cancer doesn’t fly
business class.
Neither do we.
Most cancer charities can’t tell you where your money goes. We name the scientist, the institution, the TRL level, and the cancer type. Every grant. Every dollar.
How you can help.
Every action moves the science forward. Choose the path that fits you.
Fund Research
Your donation goes directly to TRL 3–5 research at verified institutions. 85 cents of every dollar. Tracked to the grant.
Corporate Partnership
Align your brand with verifiable science. Named researcher, named institution, named TRL level. Not pink-washing — proof.
Spread the Word
Share our mission. Follow our research updates. Help us reach the people who believe science should come first.
Built to be lean.
Not aspirational.
85 cents of every dollar funds research. 15 cents runs the entire operation. This isn’t a target. It’s a constraint encoded in our bylaws.
Breast Cancer and other Female Cancers
We fund research across all female gender-related cancers: gynaecological cancers that only affect women, plus breast cancer.
Tile colour reflects research attention and funding. Lightest pinks mark the cancers most commonly discussed — deeper pinks highlight the rare and under-researched ones that receive far less support.
Breast
Most common
Cervical
Preventable
Ovarian
Silent killer
Fallopian tube
Often grouped with ovarian
Womb (uterine)
Rising incidence
Vaginal
Very rare
Vulval
Under-researched
“We name the scientist, the institution, and the exact TRL level your donation funded.”
We fund the exact gap where science dies.
Most funding goes to basic research (TRL 1–2) or late-stage trials (TRL 6–9). The critical middle is chronically underfunded. Pharma won’t touch it. Governments overlook it. We exist to fill that gap.
Why this gap kills breakthroughs
TRL 3–5 is where discoveries have proven their concept but can’t attract pharmaceutical investment. A BRCA marker identified at Queen’s Belfast. A detection method validated at MD Anderson. Without bridge funding, this science simply dies. We make sure it doesn’t.
Proof of concept
The science works in the lab. Needs validation in relevant biological systems.
Validated in models
Results confirmed in disease models. The mechanism is real. Capital needed.
Pre-clinical evidence
Strong data. The tipping point where pharma pays attention — if science gets here.
“The gap between discovery and cure isn’t scientific — it’s financial.”
Named researchers.
Verified institutions.
Follow the science.
Named scientists at verified institutions, doing published work you can look up yourself.
Prof. Kienan Savage — Molecular Oncology
Every grant is evaluated by independent scientists before a single dollar moves. Rigour only.
Follow the money. Every step.
You donate
Tax-deductible. Secure via Stripe or PayPal. Tracked from arrival.
SRAC reviews
Independent scientists evaluate for rigour and TRL 3–5 alignment.
Grants awarded
85% flows to approved research. Named institution. Named researcher.
Results published
Open updates. Annual reports. Full financial transparency.
The faces behind the science.
Real researchers. Real breakthroughs. Stories from the labs your donations fund.
A BRCA breakthrough in Belfast
How a TRL 3 discovery at Queen’s University Belfast moved closer to clinical validation — funded by donors like you.
Ovarian cancer detection at MD Anderson
Early-stage detection research that could change survival rates — currently at TRL 4 and advancing.
Cervical cancer prevention in Mumbai
Tata Medical Centre researchers developing affordable screening methods for underserved populations.
ONE WORLD | ONE FIGHT
Monthly donors receive quarterly briefings — named researchers, real results, actual science.
Donate nowGlobal PinkRibbon Map
One movement, 96 countries. Every highlighted nation stands with PinkRibbon International.
